An update on the current and emerging targeted agents in metastatic colorectal cancerEdward Chu
Division of Hematology Oncology, Department of Medicine and University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, PA, USA
Clin Colorectal Cancer 11:1-13. 2012
....
Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancerYaguang Xi
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36688, USA
BMC Genomics 7:68. 2006
....
Thymidylate synthase inhibitors as anticancer agents: from bench to bedsideEdward Chu
Cancer Center 111D, VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA
Cancer Chemother Pharmacol 52:S80-9. 2003
..The future success of TS inhibitor compounds in the clinic may depend on novel strategies to selectively inhibit TS and on novel combination therapies to overcome cellular drug resistance...
Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapyEdward Chu
Yale University School of Medicine, New Haven, Connecticut 06520, USA
J Support Oncol 4:243-50. 2006
..Except for significantly higher QOL scores at baseline, results for the cohort of colorectal cancer patients were similar to those for patients with other cancer types in the main study population...
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancerEdward Chu
Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer 115:1412-23. 2009
..In this study, the authors measured the cost of chemotherapy-related complications during treatment with capecitabine- and 5-FU-based regimens...
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparisonEdward Chu
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
Clin Colorectal Cancer 9:229-37. 2010
..This study quantified the costs associated with the acquisition of chemotherapy, its administration, and the management of chemotherapy-related complications, and their effect on total patient expenditures...
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancerEdward Chu
Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Oncology 77:244-53. 2009
..To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection...
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancerJames J Lee
Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Clin Colorectal Cancer 7:S16-20. 2007
..This review will update the current status of these capecitabine-based combination regimens...
Translational autoregulation of thymidylate synthase and dihydrofolate reductaseNingwen Tai
Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VACT Healthcare System, New Haven, CT 06516, USA
Front Biosci 9:2521-6. 2004
..Moreover, we present evidence showing that abrogation of these normal translational autoregulatory feedback mechanisms provides the molecular basis for the rapid development of cellular drug resistance...
Identification of a cis-acting element of human dihydrofolate reductase mRNANingwen Tai
Department of Medicine and Pharmacology, Developmental Therapeutic Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Biochem Biophys Res Commun 369:795-800. 2008
..This work provides new insights into the essential molecular elements that mediate RNA-protein interactions...
Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNANingwen Tai
Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Biochem J 378:999-1006. 2004
..In vitro and in vivo studies further localized this cis-element to an 82 nt sequence corresponding to nt 401-482. This work provides new insights into critical elements that mediate RNA-protein interactions...
Current therapies for advanced colorectal cancerSandhya Aggarwal
Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
Oncology (Williston Park) 19:589-95. 2005
..The goal of such studies is to facilitate the evolution of empiric chemotherapy to individually tailored treatments for patients with colorectal cancer...
First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancerJames J Lee
Section of Medical Oncology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Clin Colorectal Cancer 6:S42-6. 2007
....
Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compoundsJohn C Schmitz
Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VACT Cancer Center IIID, VACT Healthcare System, 950 Campbell Avenue, West Haven, CT 06516, USA
Cancer Res 64:1431-5. 2004
..These studies suggest that TS-targeted siRNAs are effective inhibitors of TS expression and may have therapeutic potential by themselves or as chemosensitizers in combination with TS inhibitor compounds...
Role of cysteine amino acid residues on the RNA binding activity of human thymidylate synthaseXiukun Lin
Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Healthcare System, New Haven, CT 06520, USA
Nucleic Acids Res 31:4882-7. 2003
..Taken together, these findings identify Cys-180 as a critical residue for the in vitro and in vivo translational regulatory effects of human TS...
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancerShivaani Kummar
Department of Medicine and Pharmacology, Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
Clin Colorectal Cancer 10:85-96. 2011
..Treatment with PHY906 did not alter the pharmacokinetics of 5-FU, irinotecan, or the irinotecan metabolite SN-38...
An update on treatment advances for the first-line therapy of metastatic colorectal cancerJames J Lee
Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
Cancer J 13:276-81. 2007
....
Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry techniqueWei Zhang
Department of Pharmacology, Section of Medical Oncology, Yale School of Medicine, New Haven, CT 06520, USA
Biochem Pharmacol 82:411-7. 2011
..This LC/MS/MS assay is simple, fast, and sensitive, and it represents a significant advance over previously published methodologies...
Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancerEdward Chu
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
Clin Colorectal Cancer 5:S60-1. 2005
Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cellsAbby L Mulkeen
Department of Surgery, Yale Cancer Center, New Haven, Conn, USA
Arch Surg 141:367-74; discussion 374. 2006
..CONCLUSION: Colon cancer cells expressing VEGF and VEGFR-2 may possess an autocrine growth pathway that can be effectively targeted using RNA interference as an antiangiogenic therapy...
Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategiesMuhammad Wasif Saif
Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8032, USA
Oncology (Williston Park) 20:11-9. 2006
..In this article we review various treatment options, including cytotoxic and targeted agents, currently available for patients with mCRC...
Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomesM Wasif Saif
Developmental Therapeutics Program, Yale Cancer Center, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
J Natl Cancer Inst 101:1543-52. 2009
..We review the data on pharmacokinetically guided dose adjustment of 5-FU and discuss the potential of this approach to advance therapeutic outcomes...
Identification of critical amino acid residues on human dihydrofolate reductase protein that mediate RNA recognitionNingwen Tai
Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine and VA Connecticut Healthcare System, New Haven, CT 06520, USA
Nucleic Acids Res 30:4481-8. 2002
....
Biology of colorectal cancerMuhammad Wasif Saif
From the Section of Medical Oncology and Developmental Therapeutics Program, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA
Cancer J 16:196-201. 2010
..These targeted therapies can then be used alone or in combination with standard cytotoxic chemotherapy regimens...
Thymidylate synthase as a translational regulator of cellular gene expressionJun Liu
Department of Medicine and Pharmacology, Yale Cancer Center, Yale University School of Medicine, USA
Biochim Biophys Acta 1587:174-82. 2002
..Finally, the ability of TS to function as a translational regulator may have important consequences with regard to the development of cellular resistance to various anticancer drugs...
Lessons learned from the Saltz and Mayo Clinic regimensEdward Chu
Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA
Clin Colorectal Cancer 2:13. 2002
Can metastatic colorectal cancer be cured?David L Bartlett
Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15232, USA
Oncology (Williston Park) 26:266-75. 2012
..This article reviews the main issues that must be considered from the surgical oncology and medical oncology perspectives, respectively...
A novel methionine-based signaling mechanism regulating the expression of thymidylate synthaseEdward Chu
Department of Medicine, Yale Cancer Center, Yale School of Medicine, West Haven, Connecticut, USA
Cancer Biol Ther 2:370-1. 2003
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancerJohn Murren
Yale-New Haven Cancer Center, New Haven, CT, USA
Invest New Drugs 23:123-35. 2005
..CONCLUSIONS: The MTD and recommended dose for phase II trials is 305 mg/m(2) every six weeks. Phase II trials in less heavily pre-treated patient populations are warranted...
Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)Wei Zhang
Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
J Chromatogr A 1217:5785-93. 2010
..These findings demonstrated that LC/MS/MS was and effective and reliable method for studying the parent chemicals of the Chinese herbal medicine PHY906 and their metabolites in a patient with metastatic colorectal cancer...
A history of cancer chemotherapyVincent T DeVita
Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Res 68:8643-53. 2008
..Today, chemotherapy has changed as important molecular abnormalities are being used to screen for potential new drugs as well as for targeted treatments...
New developments at the American Society of Clinical Oncology Gastrointestinal Cancers SymposiumEdward Chu
Chief, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT
Clin Colorectal Cancer 4:358. 2005
Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitorsJohn C Schmitz
VACT Healthcare System, VACT Cancer Center, West Haven, CT, USA
Silence 2:1. 2011
..abstract:..
Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new eraRoland El-Ghazal
Hospital of St Raphael, New Haven, CT, USA
Clin Colorectal Cancer 10:142-5. 2011
..This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management...
The role of a drug holiday: even patients with cancer need a vacationEdward Chu
Clin Colorectal Cancer 6:182. 2006
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancersEverett E Vokes
The University of Chicago Medical Center and Cancer Center Chicago, Illinois, USA
Oncology (Williston Park) 20:15-25. 2006
..Ongoing trials continue to investigate both the monoclonal antibodies and TKIs in various treatment settings...
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002Kavita Maung
Clin Colorectal Cancer 2:140-5. 2002
The role of a drug holiday: revisitedEdward Chu
Clin Colorectal Cancer 6:554-5. 2007
Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expressionEdward Chu
Clin Colorectal Cancer 7:162. 2008
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 studyEdward Chu
Clin Colorectal Cancer 7:226. 2008
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008Tara Beers Gibson
Clin Colorectal Cancer 7:233-9. 2008
The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancerErin Grothey
Clin Colorectal Cancer 6:621-4. 2007
The role of stool DNA analysis in the early detection and screening of colorectal cancerEdward Chu
Clin Colorectal Cancer 3:9. 2003
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancerEdward Chu
J Clin Oncol 26:2224-6; author reply 2228. 2008
Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cellsJingfang Ju
Cancer Genomics Laboratory, Mitchell Cancer Institute USA, Mobile, Alabama 36688, USA
Clin Cancer Res 13:4245-51. 2007
..The purpose of the study is to investigate the regulation of p53 expression in response to 5-fluorouracil (5-FU) in human colon cancer cells...
Adjuvant therapy: new treatment optionsEdward Chu
Clin Colorectal Cancer 4:219-20. 2004
Dihydopyrimidine dehydrogenase: a critical molecular biomarker for 5-Fluorouracil toxicityEdward Chu
Clin Colorectal Cancer 4:150. 2004
Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancerEdward Chu
Clin Colorectal Cancer 4:16. 2004
Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancerEdward Chu
Clin Colorectal Cancer 3:205. 2004
The role of thymidylate synthase as a molecular biomarkerAntontello DiPaolo
Clin Cancer Res 10:411-2. 2004
Validation of the role of angiogenesis as a chemotherapeutic targetEdward Chu
Clin Colorectal Cancer 3:74-5. 2003
Clinical colorectal cancer: the epidermal growth factor receptor signaling pathway as a chemotherapeutic targetEdward Chu
Clin Colorectal Cancer 2:202-3. 2003
Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instabilityLori Johnson
Clin Colorectal Cancer 2:146-8. 2002
Oxaliplatin: a welcome addition to our therapeutic armamentariumEdward Chu
Clin Colorectal Cancer 2:72. 2002
The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancerEdward Chu
Clin Colorectal Cancer 4:292. 2005
Making sense out of antisense thymidylate synthaseEdward Chu
Clin Colorectal Cancer 5:12. 2005
Adjuvant therapy: new treatment options with oxaliplatin-based chemotherapyEdward Chu
Clin Colorectal Cancer 5:80-1. 2005
Targeted therapyEdward Chu
Clin Colorectal Cancer 6:336. 2007
2006 - the year in reviewEdward Chu
Clin Colorectal Cancer 6:256-7. 2006
The potential role of gene profiling in the management of early-stage colon cancerEdward Chu
Clin Colorectal Cancer 6:99. 2006
Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancerEdward Chu
Clin Colorectal Cancer 6:13. 2006
Sequence analysis and functional study of thymidylate synthase from zebrafish, Danio rerioChangqing Du
Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China
J Biochem 139:913-20. 2006
..1-CMV/TS, was constructed which targeted the protein-coding region of zebrafish TS mRNA. Significant change in the development of tail and epiboly was found in zebrafish embryos microinjected pSilencer4.1-CMV/TS siRNA expression vector...
Colorectal cancer awareness monthEdward Chu
Clin Colorectal Cancer 5:389. 2006
Clinical colorectal cancer: new advances in screeningEdward Chu
Clin Colorectal Cancer 5:312. 2006
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicitySae Hee Ko
Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
Clin Cancer Res 12:289-97. 2006
..The mechanism of this synergy seems to be through an augmentation, by hyperthermia, of the antiproliferative and proapoptotic effects of temozolomide...
Lessons learned from Mother NatureEdward Chu
Clin Colorectal Cancer 5:232. 2005
Colorectal cancer: targeting metastasis and angiogenesisEdward Chu
Clin Colorectal Cancer 1:200. 2002